Diagnos Inc., a Canadian corporation trading on the TSX Venture Exchange under the symbol ADK, has announced a strategic engagement with Investor Brand Network for corporate communication and awareness services. The agreement, effective January 10, 2026, involves monthly compensation of US$6,400 payable in advance from the company's funds and remains subject to acceptance by the TSX Venture Exchange.
The company, which also trades on the OTCQB as DGNOF and on the Frankfurt Stock Exchange as 4D4A, specializes in early detection of critical eye-related health problems using artificial intelligence technology. Diagnos aims to provide healthcare clinicians with enhanced diagnostic tools to improve accuracy, streamline workflows, and achieve better patient outcomes globally.
Under the terms of the engagement, IBN will assist Diagnos in refining and strengthening its market awareness profile with the objective of maximizing shareholder value. The relationship is conducted at arm's length, with IBN and its principals holding no direct or indirect interest in Diagnos securities. Additional information about the company is available at https://www.diagnos.com and through regulatory filings at https://www.sedarplus.com.
This corporate communications initiative represents a strategic move for Diagnos as it seeks to increase visibility within the investment community and broader market. The engagement with IBN provides access to specialized communications services through the InvestorWire platform, which offers wire-grade press release syndication, article distribution to over 5,000 outlets, enhanced press release optimization, and social media distribution to millions of followers.
For business and technology leaders monitoring the intersection of healthcare and artificial intelligence, this development signals Diagnos's commitment to strategic growth and market positioning. The company's focus on AI-powered early detection systems addresses significant challenges in healthcare diagnostics, particularly in ophthalmology where early intervention can prevent vision loss and reduce long-term treatment costs.
The broader implications of this announcement extend to the healthcare technology sector, where effective communication strategies can influence investment, partnerships, and adoption of innovative solutions. As AI continues to transform medical diagnostics, companies like Diagnos that combine technological innovation with strategic market positioning may gain competitive advantages in attracting both clinical adoption and investor interest.
Investors and industry observers can access the latest news and updates relating to DGNOF through the company's newsroom at https://ibn.fm/DGNOF. The full press release detailing the engagement is available at https://ibn.fm/NRVea.
